BioLineRx (BLRX) Tops Q1 EPS by 10c

Go back to BioLineRx (BLRX) Tops Q1 EPS by 10c

Jones Trading Reiterates Hold Rating on BioLineRx (BLRX)

May 28, 2025 8:59 AM EDT

Jones Trading analyst Justin Walsh reiterated a Hold rating on BioLineRx (NASDAQ: BLRX).

The analyst comments "APHEXDA will provide a steady stream of royalties that support earlier stage development of assets expected to be in-licensed in 2025-2026, most likely in the oncology and/or... More